These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 17699365)

  • 1. Multiple myeloma.
    Singhal S; Mehta J
    Clin J Am Soc Nephrol; 2006 Nov; 1(6):1322-30. PubMed ID: 17699365
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiple myeloma--an update on diagnosis and treatment.
    Caers J; Vande broek I; De Raeve H; Michaux L; Trullemans F; Schots R; Van Camp B; Vanderkerken K
    Eur J Haematol; 2008 Nov; 81(5):329-43. PubMed ID: 18637123
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of multiple myeloma in the targeted therapy era.
    Saad AA; Sharma M; Higa GM
    Ann Pharmacother; 2009 Feb; 43(2):329-38. PubMed ID: 19193585
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Current and future approaches to therapy for multiple myeloma].
    Nara N
    Gan To Kagaku Ryoho; 1995 Jan; 22(1):9-15. PubMed ID: 7826084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Initial bone marrow findings in multiple myeloma. Significance of plasma cell nodules.
    Buss DH; Prichard RW; Hartz JW; Cooper MR; Feigin GA
    Arch Pathol Lab Med; 1986 Jan; 110(1):30-3. PubMed ID: 3753566
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatic and renal plasma cell lesions in a patient with multiple myeloma in hematological remission.
    Galani Z; Viniou N; Kyrtsonis MC; Sachanas S; Antoniou T; Dimopoulou MN; Vassilakopoulos TP; Korkolopoulou P; Nakopoulou L; Patsouris E; Pangalis GA
    Anticancer Res; 2007; 27(1B):571-4. PubMed ID: 17348443
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The evolution and impact of therapy in multiple myeloma.
    Laubach JP; Richardson PG; Anderson KC
    Med Oncol; 2010 Jun; 27 Suppl 1():S1-6. PubMed ID: 20169425
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Myelosuppression associated with novel therapies in patients with multiple myeloma: consensus statement of the IMF Nurse Leadership Board.
    Miceli T; Colson K; Gavino M; Lilleby K;
    Clin J Oncol Nurs; 2008 Jun; 12(3 Suppl):13-20. PubMed ID: 18490253
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Infections in patients with multiple myeloma in the era of high-dose therapy and novel agents.
    Nucci M; Anaissie E
    Clin Infect Dis; 2009 Oct; 49(8):1211-25. PubMed ID: 19769539
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lenalidomide and its role in the management of multiple myeloma.
    Falco P; Cavallo F; Larocca A; Liberati AM; Musto P; Boccadoro M; Palumbo A
    Expert Rev Anticancer Ther; 2008 Jun; 8(6):865-74. PubMed ID: 18533796
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of relapsed/refractory multiple myeloma.
    Kastritis E; Palumbo A; Dimopoulos MA
    Semin Hematol; 2009 Apr; 46(2):143-57. PubMed ID: 19389498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bone marrow angiogenesis and angiogenic factors in multiple myeloma treated with novel agents.
    Cibeira MT; Rozman M; Segarra M; Lozano E; Rosiñol L; Cid MC; Filella X; Bladé J
    Cytokine; 2008 Mar; 41(3):244-53. PubMed ID: 18178097
    [TBL] [Abstract][Full Text] [Related]  

  • 13. State of the art therapy in multiple myeloma and future perspectives.
    Denz U; Haas PS; Wäsch R; Einsele H; Engelhardt M
    Eur J Cancer; 2006 Jul; 42(11):1591-600. PubMed ID: 16815703
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bortezomib in the front-line treatment of multiple myeloma.
    Richardson PG; Mitsiades C; Schlossman R; Ghobrial I; Hideshima T; Munshi N; Anderson KC
    Expert Rev Anticancer Ther; 2008 Jul; 8(7):1053-72. PubMed ID: 18588451
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted treatments to improve stem cell outcome: old and new drugs.
    Raab MS; Breitkreutz I; Anderson KC
    Bone Marrow Transplant; 2007 Dec; 40(12):1129-37. PubMed ID: 17768392
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multiple myeloma: charging toward a bright future.
    Katzel JA; Hari P; Vesole DH
    CA Cancer J Clin; 2007; 57(5):301-18. PubMed ID: 17855486
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical significance of bone marrow biopsy and plasma cell morphology in MM and MGUS.
    Bartl R; Frisch B
    Pathol Biol (Paris); 1999 Feb; 47(2):158-68. PubMed ID: 10192882
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical updates and nursing considerations for patients with multiple myeloma.
    Faiman B
    Clin J Oncol Nurs; 2007 Dec; 11(6):831-40. PubMed ID: 18063542
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New drugs in multiple myeloma.
    Berenson JR; Yellin O
    Curr Opin Support Palliat Care; 2008 Sep; 2(3):204-10. PubMed ID: 18685422
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel therapies in myeloma.
    Hayden PJ; Mitsiades CS; Anderson KC; Richardson PG
    Curr Opin Hematol; 2007 Nov; 14(6):609-15. PubMed ID: 17898564
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.